Related references
Note: Only part of the references are listed.Response to afatinib in treatment-naive patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases
Shih-Hong Li et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Nicolas Girard
FUTURE ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases
Kathryn C. Arbour et al.
CANCER (2018)
Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice
Shi-rong Zhang et al.
ACTA PHARMACOLOGICA SINICA (2017)
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis
Yo Kawaguchi et al.
CHEMOTHERAPY (2017)
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
James Chih-Hsin Yang et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Myung-Ju Ahn et al.
LANCET RESPIRATORY MEDICINE (2017)
Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
Chukwuka Eze et al.
FRONTIERS IN ONCOLOGY (2017)
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents
Marwan Ghosn et al.
BULLETIN DU CANCER (2017)
Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases
Maximilian Hochmair et al.
ANTI-CANCER DRUGS (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer
Haa-Na Song et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
Martin Schuler et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Paula Mulvenna et al.
LANCET (2016)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Zhenfan Yang et al.
Science Translational Medicine (2016)
The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
Xu Yufen et al.
SPRINGERPLUS (2016)
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
D. Planchard et al.
ANNALS OF ONCOLOGY (2015)
Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Qingbei Zeng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
Justine L. Kuiper et al.
LUNG CANCER (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
Toshihiko Iuchi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
Siow Ming Lee et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Dong-Yeop Shin et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Afatinib combined with cetuximab for lung adenocarcinoma with leptomeningeal carcinomatosis
Chou-Han Lin et al.
LUNG CANCER (2014)
Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
Karmen Stanic et al.
RADIOLOGY AND ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer
Yanming Deng et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non-Small-Cell Lung Cancer
James W. Welsh et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Analysis of Treatment Outcomes of Intraventricular Chemotherapy in 105 Patients for Leptomeningeal Carcinomatosis from Non-Small-Cell Lung Cancer
Ho-Shin Gwak et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer
Eunyoung Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
Hongqing Zhuang et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study
Yin-Duo Zeng et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
Yosuke Togashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Treatment of Leptomeningeal Spread of NSCLC: A Continuing Challenge
Seema Nagpal et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2012)
Leptomeningeal Metastasis from Non-small Cell Lung Cancer Survival and the Impact of Whole Brain Radiotherapy
Patrick G. Morris et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline
May N. Tsao et al.
PRACTICAL RADIATION ONCOLOGY (2012)
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
Martin Kocher et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High-dose Erlotinib for Refractory Brain Metastases in a Patient with Relapsed Non-small Cell Lung Cancer
Akito Hata et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer
Jennifer L. Clarke et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis
Inan Olmez et al.
LUNG CANCER (2010)
Leptomeningeal metastases in the MRI era
J. L. Clarke et al.
NEUROLOGY (2010)
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
A-M. Ruppert et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
PHASE I STUDY OF CONCURRENT WHOLE BRAIN RADIOTHERAPY AND ERLOTINIB FOR MULTIPLE BRAIN METASTASES FROM NON-SMALL-CELL LUNG CANCER
Joline S. W. Lind et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib
Tatsuya Katayama et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population
Shenglin Ma et al.
LUNG CANCER (2009)
Leptomeningeal metastasis
William P. O'Meara et al.
CURRENT PROBLEMS IN CANCER (2007)
Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases - Survey by outcome research network for evaluation of treatment results in oncology
Luca Moscetti et al.
CANCER (2007)
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
David M. Jackman et al.
CLINICAL CANCER RESEARCH (2006)
Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by Erlotinib (Tarceva)
P Chinnaiyan et al.
CANCER RESEARCH (2005)
Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial
GL Ceresoli et al.
ANNALS OF ONCOLOGY (2004)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
The seed and soil hypothesis: vascularisation and brain metastases
IJ Fidler et al.
LANCET ONCOLOGY (2002)
Share Paper
